Smoking is a choice, not a compulsion

Smoking is a choice, not a compulsion

By Christopher Russell
The official view of nicotine addiction states that while initial smoking is voluntary, nicotine gradually changes the normal processes of neurotransmission within the brain’s reward system which make it increasingly difficult for smokers to control when and how much they smoke. As people continue to smoke, they are believed to eventually pass a ‘tipping point’, as if a switch has been flipped in their brains, at which “to smoke or not to smoke is not a question of free will of the individual, because nicotine makes people to depend on her, thereby reducing their capacity for making free choices.” (Ochoa, 1994: 196–197). In other words, smokers are no longer merely smokers; they are now nicotine addicts whose smoking is physically compelled, no longer under their willful control. This medical explanation for why some people continue to smoke despite their stated desire to quit is endorsed by several authoritative health bodies including the World Health Organisation, American Medical Association, and the American Psychiatric Association, provides justification for tobacco control measures and the provision of medical treatment to quitting smokers, and is largely accepted by smokers and the general public as an unquestioned, scientifically-proven truth of nicotine addiction.
It may be surprising to some readers then to learn that the argument that certain smokers are physically unable to stop smoking is actually consistently and critically undermined by a large body of empirical evidence and logical argument. On the contrary, what we can show is that some people find quitting smoking to be easy, a bit hard, quite hard, or extremely difficult, and that people keep smoking and quit smoking because they choose to for their own reasons, not because they are caused to. Though an extensive review of research is not possible here, this article describes what I consider to be among the strongest arguments for viewing smoking always as a choice, not as a physically compelled act.
Nicotine withdrawal severity does not distinguish those who do quit from those who don’t quit
The medical explanation is built on the assumption that nicotine withdrawal severity, as a measure of dependence, should predict who is most able, less able, and unable to stop smoking, and promises that medical research will soon find a more effective treatment for reducing nicotine withdrawal severity. However, no conclusive evidence of a relationship between withdrawal syndrome severity and quit outcome has yet been observed.
In a review of fifteen prospective studies of the strength of severity of withdrawal symptoms as predictors of quit outcome, Patten and Martin (1996) found that only six studies reported a relationship between withdrawal severity and quit outcome with the remaining nine reporting only weak relationships between withdrawal symptom intensity and frequency and short- and long-term relapse. In some studies, quitters reporting moderately severe symptoms lapsed to smoking within hours whereas people who reported severe withdrawal distress were are able to forego smoking for days and even weeks. Furthermore, most research has found that withdrawal symptoms largely resolve within two to three weeks following cessation and most affective symptoms resolve within three to four weeks yet the tendency to relapse to smoking persists for several years following cessation, long after withdrawal symptoms should have abated. Such incongruence between the temporal courses of withdrawal emergence and relapse potential suggests they are only weakly related.
Furthermore, in opposition to claims that NRT produces smoking cessation by alleviating the severity of the nicotine withdrawal syndrome, the extent to which NRTs suppress withdrawal symptoms has not been found to correspond well with their ability to produce abstinence. I’ve chosen two of many studies which found this poor correspondence. In Jorenby and colleagues (1995) study, though a forty-four milligram transdermal nicotine patch further reduced participants’ craving for nicotine than a twenty-two milligram patch, this reduction was not related to success in maintaining abstinence as smoking cessation did not differ significantly between the two patch groups at either eight weeks or twenty-six weeks following the quit date.
Alternatively, in a study by the Transdermal Nicotine Study Group (1991), though a twenty-one milligram transdermal nicotine patch produced a better abstinence rate at six months post-quit than a fourteen milligram patch and placebo treatment, abstinence rates across groups did not associate with changes in self-reported withdrawal symptom severity. This lack of a consistent association between withdrawal severity and quit outcome raises questions about the mechanisms of action and the psychosocial aspects of NRT.
Belief in the addictiveness of nicotine as a better predictor of quit success
There is better evidence that withdrawal symptoms are temporary rather than enduring obstacles, the effects of which are mediated by cognitive factors such as self-control ability, belief in the addictiveness of nicotine, and perceived self-efficacy. The belief that nicotine is addictive seems to increase the salience of withdrawal symptoms, thereby adding to their unpleasantness and increasing the chances of relapsing. In making symptoms more salient, a belief in the addictiveness of nicotine may lead quitters to overestimate the strength of these symptoms, therefore believing that they at greater risk of lapsing back to smoking than is actually posed by pure pharmacology. However, there is also evidence for the inverse hypothesis; frequent failure to stop smoking leads the smoker explain these failures as due to the fact that he is physically addicted and is incapable of stopping.
The main reason given by smokers for their failure to stop smoking is that they see themselves as addicted, and many smokers are very willing to describe themselves as “addicts” on the back of cessation failures. From a functional perspective, attributing smoking to a physical disease is attractive because the “addict” label allows smokers to claim diminished responsibility for their behaviour, diminished free will to control their behaviour, and so, justification for discontinuing their efforts to quit without assistance. Therefore, regardless of its legitimacy, disseminating the message that some smokers have lost the ability to control their smoking should be counter-productive to the goal of persuading our populations to quit smoking.
Most people quit smoking without assistance, medical or otherwise.
What we can and cannot show about the nature of nicotine addiction today is summed up by Akers (1991), a sociologist:
“The problem is that there is no independent way to confirm that the “addict” cannot help himself and therefore the label is often used as a tautological explanation of the addiction. The habit is called an addiction because it is not under control but there is no way to distinguish a habit that is uncontrollable from one which is simply not controlled”.
As an identifiable pharmacological substrate which compels smoking is yet to be found, the only evidence we have that people can’t stop is people say they can’t stop or are observed as not stopping. We cannot observe that people cannot stop; only that people do not stop. Conversely, the best evidence we have that people can stop is that they often do stop in large numbers, and more often without medical intervention or a painful withdrawal experience. Indeed, despite the staunch promotion of nicotine replacement products as the best hope for those trying to quit and in opposition to media messages that quitting is more likely with the use of nicotine replacement products, population studies consistently show that unassisted cessation is by far the most effective quitting method, leading the second most effective method – nicotine replacement therapy – by a large distance (see Chapman, 2010). For example, in 1986, the American Cancer Society reported that “over 90% of the estimated 37 million people have stopped smoking in the US since the Surgeon General’s first report linking smoking to cancer (in 1964) have done so unaided” (i.e. without the help of a formal treatment method). During a similar time frame, a report by the United States Department of Health, Education and Welfare also estimated that 95% of those who have quit smoking have done so on their own (USDHEW, 1977) This suggests that, for these 90-95% of Americans, quitting smoking was a matter of changing their minds about smoking however this change of mind came about, not through pharmaceutical intervention. It is somewhat puzzling then that unassisted quitting is rarely advised to smokers and no public education campaigns to my knowledge carry statistics for unassisted cessation or promote unassisted cessation as an effective strategy.

Lastly, in contrast to the popular belief that smokers typically plan their quit attempt in advance and that such advance planning leads to longer cessation, West and Sohal (2006) found that 48.6% cent of smokers put their most recent quit attempt into effect immediately after the decision to quit was made and, compared to those who planned their quit attempt in advance, those who quit on the spot were 2.6 times more likely to still be not smoking six months later. More recently, Ferguson and colleagues (2009) similarly found that the odds of a “spontaneous” quit attempt lasting for 6 months or longer were twice that of quit attempts planned in advance. These favourable findings for spontaneous as opposed to planned, assisted quitting fit with many smokers’ stories of giving up because they just felt like it; they had just had enough; a friend was dying of lung cancer; they themselves had a brush with death; or they had just found out that they were to become a parent or grandparent, among many other reasons for quitting on the spot. Successful, unplanned quitting happens seems to happen because a sudden switch in motivation changes our view of smoking from something positive to something which threatens an important part of our life.

The main point here is that quitting smoking appears to not depend on treating a physical addiction to nicotine, but on us becoming addicted to other ways of living and seeing smoking as something which interferes with these more valued ways of living. Simply, it appears that people smoke when it makes sense to smoke and stop smoking when smoking stops making sense.
Why brain pharmacology cannot explain why people smoke
Pharmacological processes of nicotine merely provide an on-line explanation of what happens to people’s brains and bodies when nicotine is consumed (i.e. the causes); they do not provide retrospective explanation for why people use nicotine (i.e. the reasons). There is good evidence that nicotine can make quitting hard; there is no evidence that a nicotine-induced pharmacological substrate compels people to put cigarettes in their mouths. Essentially, asking what happens when a person smokes is to ask about the involuntary neuroadaptation and gene expression which are caused; to ask why he smoked is to ask about the plethora of intra- and inter-individual reasons for voluntarily putting a cigarette to mouth and lighting. These are two very different sets of phenomena which require different levels of explanation.
The fact that millions of people say they are addicted is not evidence that they are addicted; the vast majority of people who say at one point “I can’t stop smoking” then do stop smoking! Unfortunately, physicians and tobacco control bodies tend to take these “I’m addicted!” claims as if they were literally true, solid pieces of evidence of an actual physical disease! But no other true physical disease is diagnosed solely on what people say they can and cannot do. We would certainly be suspicious if our physician diagnosed us as having diabetes without conducting any physical tests. We wouldn’t allow it; we would demand that tests be conducted before accepting the diagnosis and starting a course of treatment. But this is not how we currently ‘diagnose’ nicotine addiction and not how doctors decide to prescribe a course of nicotine replacement products; these decisions are made on the basis of how people talk about their smoking, not on what can objectively be observe in their brains and bodies.
A confusion of outcomes with intentions
While I do not dispute that tobacco smoking is associated with the onset of several bodily diseases, the act of smoking itself is not symptomatic of a disease. That people die from smoking says nothing about whether they were able to stop smoking at any point; it only says that they didn’t stop. That bad things happen as a result of smoking also does not make the decision to smoke a pathological decision, just as injury or death due to climbing mountains at the peak of winter does not mean that the decision to go mountain climbing, with all the foreknowledge of the potential risks, was a pathological decision. We must remember that people do risky things every day, many of which have the potential to kill on the spot, but the outcome of doing these behaviors says nothing about why these behaviors were instigated.
What medications do and do not do for smokers
Of course, I do not deny that the uses of medications like bupropion make it easier to forego smoking by blocking parts of the brain which can increase the pleasure obtainable through smoking. I would encourage people to use these medications if they find it helps them to not abstain from smoking. However, reducing the difficulty of quitting should not be confused with restoring the individual’s ability to quit as if this ability was at any point lost. Medications can help people quit smoking and great strides are being made to manufacture medications which make the process of quitting more tolerable. However, these medications are not necessary for controlling smoking in the way heart medicines, radiation therapy, and insulin are necessary to stave off the mortal threats of heart diseases, cancers, and diabetes respectively. These groups of people unfortunately do not have agency over their conditions in the way smokers have over their smoking.
No medication has yet been shown to restore a smoker’s free will to reject cigarettes. Additionally, manufacturing medications has long been considered by addiction researchers such as Bruce Alexander, Stanton Peele, and John Davies to be focusing on the thin edge of the wedge; too much focus on the uses of medication, they would argue, restricts the need for drug users and treatment providers to consider a broad social analysis of why tens of millions of people start or continue to light up each day.
Conclusion
The evidence in several domains combine to suggest that the nature of nicotine addiction is not well explained by nicotine pharmacology alone, but rather, that the evidence depicts smoking as primarily a reasoned choice influenced only peripherally by the pharmacologic effects of nicotine on the brain and body. Even when accounting for the presence of severe nicotine withdrawal symptoms and intense negative emotional experience associated with smoking abstinence, a relapse to smoking is not something that is done to people, but rather, something people do. There is good evidence that smokers often fail to control their smoking but no scientific evidence that they ever lose the ability to control their smoking.
Although the medical explanation receives unwavering support from authoritative health bodies around the world, particularly in the United States, continual reformulation is required to keep it from being undermined by the facts of nicotine addiction. The view that smokers continue to smoke through choice is vehemently denied by these health bodies, deeming this explanation to be judgmental and unsympathetic, and its dissemination to be irresponsible, ill-conceived, and dangerous to those smokers who want to quit. On the contrary, this position is not harsh, judgmental, or ideological; it is based on what available evidence suggests smokers are capable of.
Current arguments about the nature of smoking were intended only to encourage those who argue for the medical model to present evidence and theory which stand up to or resolve the caveats described here. I do not contest that nicotine replacement products can make the abstinence period more physically tolerable but I would always emphasize smoking, abstinence and relapse are chosen outcomes, each of which do occur with and without the use of nicotine replacement products.
To conclude, smokers will smoke for as long as smoking makes sense to them; when smoking stops making sense, people stop smoking. The issue for the tobacco industry and health bodies then is to advertise smoking in ways which respectively reinforce the sense and senselessness in continuing to smoke.
References:
Akers, R. L. (1991). Addiction; the troublesome concept. The Journal of Drug Issues, 21(4). 777-793.
Chapman, S. & McKenzie, R. (2010). The global research neglect of unassisted smoking cessation: Causes and consequences. PLoS Medicine, 7(2), 1-6.
Ferguson, S. G., Shiffman, S., Gitchell, J. G., Sembower, M. A., & West, R. (2009). Unplanned quit attempts – Results from a U.S. sample of smokers and ex-smokers. Nicotine & Tobacco Research, 11(7), 827-832.
Jorenby, D. E., Smith, S. S., Fiore, M. C., Hurt, R. D., Offord, K. P., Croghan, I. T., et al. (1995). Varying nicotine patch dose and type of smoking cessation counselling. Journal of American Medical Association, 274, 1347–1352.
Transdermal Nicotine Study Group. (1991). Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Journal of the American Medical Association, 266, 3133–3138.
Ochoa, E. L. M., Li, L., & McNamee, M. G. (1990). Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine. Molecular Neurobiology, 4, 251–287.

Patten, C. A., & Martin, J. E. (1996). Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine, 18, 190–200.

U.S. Department of Health, Education and Welfare. (1979). Smoking and health: A report of the surgeon general. Washington, DC: Author.

West, R. J., & Sohal, T. (2006). “Catastrophic” pathways to smoking cessation: findings from national survey. BMJ, 332(7539), 458–460.

Electronic Cigarettes:

I recently picked up a copy of the Fort Lee Traveller (Vol. 70 # 46 dated November 18, 2010) – a newspaper for soldiers transiting through or based at Fort Lee, Virginia near Petersburg. Page 12 included an article by Jean Davis R.N under the heading Kenner’s Corner titled; Are Electronic Cigarettes Safe, Effective? It wasn’t a surprise to read the points made; namely;
Their safety and effectiveness is not proven.
The FDA has concerns and is classifiying them as a drug delivery device requiring regulation.
E-cigarettes contain carcinogens and diethylene glycol.
They are not an effective cessation device.
They are not endorsed by DoD, the Department of Veterans Affairs or the US Public Health Service.

All of the above is accurate and correct. Nevertheless you may like to know that;

Although not proven to be safer, because the research has not been done, it is likely that they are considerably less harmful than cigarettes. Why; because e-cigarettes don’t burn tobacco which is the major cause of most harmful constituents in tobacco. Finding some carcinogens is also not a surprise, look hard enough and you’ll find them almost anywhere. The real point is what was the dosage and how does it compare to cigarettes? It is likely to be substantially less than cigarettes a point not generally shared with the public. Why not? Because rather than migrate to something less harmful (like e-cigarettes) most public health community advisors would prefer you to quit. Period.

If you really want to quit, not just say you do – you can do it; but most smokers don’t choose to quit because they really don’t want to quit. That’s leaves them in a pickle as the public health community advises no good alternatives; but there are…
Almost any non-combustible tobacco product is less harmful than cigarettes. This includes products like snus, moist snuff and other oral tobacco products.
E-cigarettes are a non-combustible product. They don’t burn tobacco as a result they are likely to be considerably less harmful than cigarettes (albeit unproven.) They can be bought with a variety of nicotine levels and even without nicotine or tobacco!
They provde a similar sensory reward to smoking a real cigarette – there is almost no tar, only a smoke vapor and little or no sidstream smoke – to annoy / pollute your colleagues.

So why the fuss?
Big-Pharma is conerned. E-cigarettes have the potential to take market-share of their lucrative NRT (Nicotine Replacement Therapy) market. This is highly profitable and generally does little to help smokers quit so you keep buying these relatively costly products for quite a while. Some members of FDA’s scientific advisory committe (TPSAC) are accused of favoring Big-Pharma as some of its most anti-tobacco panel members are, or have been, Big-Pharma paid consultants. More on this at another time….

As usual comments welcome…………..

BIMO is going to TABEXPO 2011: Here’s why….

“In a fast-changing world where loyalties and friendships
are quickly overcome by economic necessities, BIMO
continues to be pleasantly surprised by the
renewed and sustained support we receive from
our cigarette manufacturing customers, both big
multinationals and small independents.
All of us have been hit by the crisis, by declining
markets, by financial difficulties …. Yet nowhere
else in our diverse markets have we received
the continuous and understanding patronage
than we have received from our tobacco film
business.
And that is why BIMO has chosen
to support TABEXPO 2011 Prague
with our biggest stand and
biggest spend ever.
We are mindful of how well we have
prospered thanks to the dedicated and
professional industry-specific experience of
the Tobacco Reporter organization in Paris,
Vienna, Barcelona and Geneva, my first-ever
tobacco exhibition, already 12 years ago.
Tobacco Reporter is made up of the same people,
offering the same guarantees they have made
for every event. In a very confusing moment for
choosing an event, we can’t afford any more than
the next guy to make the wrong decision and lose
the maximum return on our investment.
Therefore we’re staying with TABEXPO
2011 Prague, the same expo where we met,
welcomed, persuaded and convinced all those
great people and companies who make up our
customer base today.”

Michael Pierse
Sales Director
BIMO

NDC Infrared Engineering is going to TABEXPO Prague 2011, and here’s why…

“TABEXPO has featured as a key date in the tobacco calendar for many years now and served the industry effectively as the international forum where new business partnerships are forged, old ones refreshed and the latest developments presented to a targeted audience. In a time when many economies are still in a state of flux, TABEXPO stands out as a symbol of continuity and enables us to benchmark our performance in the context of the wider industry.
For NDC, and, we suspect, for the majority of exhibitors, TABEXPO’s value proposition extends well beyond just the number of visitors to our booth and the number of leads we collect, critical though these tangibles are: it’s the informal conversations in the aisles, the social venues and the meeting rooms that we appreciate as an essential source of news, opinion and market intelligence.
The timing and location of TABEXPO 2011 is just right with a 4 year interval between this major global show with the other regional shows ideally occurring at sensible intervals to provide industry continuity. Prague will provide us with an opportunity to launch our new products to as wider international audience as possible which it demonstrated it had the ability to facilitate at the Barcelona event. What’s more, the historic city of Prague, with its proximity to Germany and Western Europe and its ties with the East, and the Czech Republic’s reputation for engineering excellence, bode well for attract a strong international visitor profile allowing us to meet our commercial and technical objectives. It’s also a great city to visit, and easy to get to.
Wishing you all the best for a successful 2011, and looking forward to seeing you at TABEXPO.”
Dr Ian B Benson
Sales & Marketing Director
NDC Infrared Engineering

Inter-Tabac – Dortmund

Every year the Westfalenhalle exhibition center, located just south of the city of Dortmund Germany, hosts Europe’s largest retail / distribution and wholsale tobacco show. And its growing! Particpants rent more booth space and visitors flock to see products new and old from the tobacco world. Almost every conceivable tobacco product is represented in a large exhibition center which fully occupies three large halls.

The majority of attendees are German as you would expect, but there are a considerable number of attendees from most neighboring countries – the EU and even further afield – like the USA, South Africa and Israel to name a few. Interestingly it is these attendees which are increasing.

If you exhibited or attended, please give some feedback on this truely international event.

Cross Border tobacco trade – USA / Canada

We thought you may find this series of articles interesting.

http://news.nationalpost.com/2010/09/18/post-preview-inside-canadas-underground-tobacco-industry-a-five-part-series/

Please read the five associated articles and feel free to post comments below.
We welcome your feedback and comments on the subject.

Protabaco – Colombia

When PMI made a firm bid to buy Protabaco in Colombia most, including myself, thought the deal would not be turned down by the Colombian Government. We were wrong.

Now PMI (PHILIP MORRIS INTERNATIONAL) is asking Colombian regulators to reconsider their plan to buy Protabaco but it is not at all clear if the government will overturn its decision as PMI already owns what used to be rival Coltabaco – based in Medellin Colombia. Together they control 90%+ of the local Colombian market, which is around 20 billion sticks.

Colombia’s Superintendent of Industry and Commerce rejected PMI’s bid to buy Protabaco for $452 million.

Interestingly, does this open the door for rival BAT to gain entry into the Colombian market? We think it does. Watch this space or provide a comment.

Protabaco manufactures Mustang, Premier and President.

Best Sorting – Press release

Japan Tobacco Group (JT Group) approves Belgian Electronic Sorting Technologies’
(BEST) Foreign Matter Detection-system.
As the tobacco market is increasingly under pressure, facing rigorous regulations worldwide, leading
manufacturers are searching for the most efficient, premium quality control equipment. While the removal
of FM (Foreign Matter) or NTRM (Non Tobacco Related Materials) is a specific field of expertise, many
techniques and technologies apply. One of them is the ‘optical’ technology.
Market analyse on the sorting technologies
In 2008, the JT Group decided to execute a detailed market analysis on the
latest technologies used in optical FMD-systems. During this process, the JT
Group learned that the technology had greatly evolved since their existing
laser-based FMD equipments were implemented, making it impossible to
further upgrade them with the latest technologies available.
In order to compare the current units with the latest sorting technology,
a long-term evaluation test was required. The main focus was to increase
NTRM removal/sorting efficiency by decreasing error rejection levels, while
looking into the new/enhanced sorting criteria available (such as biological
characteristics of tobacco).
Following this, a series of short-term tests was executed. Further required long-term tests in a real production
environment were organised at the JTI Trier GmbH facility. These evaluations were performed during almost the whole
of 2009.
BEST provided its laser sorters
BEST Sorting provided its latest laser technology for sorting tobacco. Both its HELIUS™ free fall
laser sorter and its TB5™ high capacity belt laser sorter (with a HELIUS hardware processing
platform) were put to the stand for long-term evaluation. Each unit was integrated into the
Primary Tobacco expansion-processing line and evaluated in real production conditions by the
facility team.
The Japan Tobacco International (JTI) Global Engineering team also led several off-line tests
on PMD-conditioned Tobacco-lamina (tobacco blends incl. Virginia, Burley, Oriental and/
or reconditioned tobaccos) in different percentages. The tobacco industry evaluation testprotocol
was used (seeded tests) as JT Group’s specific targets were set forward. Criteria such
as ease of maintenance, operatability (blend management, blend changes), line integration
complexity, user-friendliness, and stability of sorting were considered during the evaluation.
Tests with HELIUS™ free fall laser sorter and the TB5™ belt laser sorter were successful. Both the sorters complied with
the high standards set forward for this evaluation and requested by the JT Group.
Press release April 19th 2010
JT Group chooses BEST for a long-term partnership
The foundation for a long-term partnership was set as the JT Group decided, after careful analyses of the parameters set
forward during the evaluation, to approve BEST’s (laser-based) FMD-systems. As a result, the JT Group has already committed
to purchase multiple BEST sorting machines for various processing plants.
Mr. Tatsuya Shimada, JTI Global Engineering FMD-evaluation project leader, said that he became convinced of the quality
of BEST’s laser sorters after rigorous testing. “Both laser sorters satisfied the criteria we set forward, and the product range
they cover will ensure that the implementation meets the specifics of our production lines.” Furthermore, Mr. Shimada
commented upon BEST’s professionalism: if any observation was made, BEST’s responsiveness and the actions they
undertook to overcome them gave JT Group a good feeling about the kind of commitment BEST is ready to make and of the
resourceful solutions BEST is able to offer. For example, when asked if a local service team could be available for Japan Tobacco
Inc. facilities in Japan, BEST committed to setting up a specific operation and hiring competent service engineers to comply
with the very specifics towards minimal intervention time. BEST also agreed to make local spare parts available. Today, as
we speak, this action has nearly been completed and BEST Japan is scheduled to be operational before the first BEST unit is
supplied to JT’s Manufacturing Technology Center in Japan.
Mr. Steven Van Geel, BEST’s Area Sales Manager for the Tobacco branch, commented: “BEST is looking forward to this
new challenging partnership. We would like to thank the JT Group for this opportunity and the time they have dedicated
to the evaluation”. He further added that BEST is committed to making each of the different sorter integration projects a
success. Furthermore, Mr. Van Geel stated that BEST will be pleased to work with the different JT Group affiliates, while a
close relationship will also need to be maintained (or built-up if not already present) with the different primary processing
equipment integrators with which JT Group has established a relation in terms of equipment-supply. “Together with the
expertise of the JT Group, its integration partner(s) and BEST, we will make sure that any of the (to be) installed sorters will be
performing in the most optimal conditions, striving for a consistent NTRM free product.”
As a leading and pioneering designer and manufacturer, BEST will pursue comprehensive market research and continuous
development to further strengthen its position on the sorting market. Currently, several new developments are being tested.
Once they are ready for commercialization, any of these solutions will have the potential to be implemented within the
existing units, without any major additional cost.
Contact information :
Steven Van Geel
Area Sales Manager
T: +32 (0)16 740 309
steven.vangeel@bestsorting.com